
This overview reports on first experience with German DRGs version 1.0 from 2003, with special regard to relevant procedures and diagnoses of anaesthesiology. Basically, the G-DRGs are a translation of the AR-DRGs 4.1. Only the 2004 version represents a first real German DRG system. Particularly anaesthesiological measures for procedures which are normally performed without narcosis can lead to essentially relevant remuneration. In intensive care medicine, the hours of artificial ventilation must be recorded exactly. In the 2004 version of the G-DRGs, intensive medical performances are mainly differentiated regarding the time of ventilation, which leads to better payment than under version 1.0. In intensive care medicine, additional remuneration is only intended for dialyses and other organ-supporting procedures. Pain therapy is insufficiently documented in the G-DRGs. Although new codes of pain treatment are included in the G-DRGs, they do not lead to relevant remuneration. Diagnoses and procedures coded by the anaesthetist should be registered in the clinic information system without delay. Only non-anaesthesia-associated diagnoses, i.e. additional diagnoses resulting from the preanaesthetic check-up of the patient in the preanaesthetic department, should be checked by non-anaesthesiological physicians. The correct documentation and transfer of ASA classifications is necessary for additional charges in external quality management and to avoid financial sanctions. In our experience, regarding operated patients, anaesthetists can contribute a lot to enquiries by health insurance companies, e.g. whether the payment code for an in- or an out-patient should be used. Departments of anaesthesia should appoint an anaesthetist as DRG representative to supervise anaesthesiological coding and DRG-relevant procedures.
Among the many technical appliances for pain therapy which are currently available, the use of implantable drug pumps for prolonged pain treatment is of increasing importance. Since this kind of pain therapy can be used without any problems outside the hospital, it improves the quality of life of the patient. Furthermore, it is combined with a reduction of side-effects which frequently occur when analgesics are given orally or parenterally in big single doses. High initial costs are compensated by a good cost-benefit ratio of this kind of pain treatment, which enables the use of analgesics in low doses in out-patients. Based on the use of gas mixtures which can be compressed repeatedly, implantable mechanically-driven pumps are a nearly inexhaustible propulsion unit for drug infusions. The development of new gas mixtures and of innovative control mechanisms allows greater independence from surrounding influences and higher precision regarding infusion rates. Mechanically-driven pumps are characterized by prolonged functioning and low cost of purchase. Therefore, they will continue to be available on the medical market in future. Special progress in cardiac pacemaker therapy as well as further miniaturization of portable infusion pumps with peristaltic propulsion have led to the development of programmed implantable pumps with lithium batteries as energy sources. The advantages of these pumps, particularly those with "externally" programmable infusion rates (continuous, bolus, periodical bolus, etc.) point to the future. With these devices, evacuation and refilling of the pumps due to necessary changes of drug concentrations, as has to be done with mechanically working pumps with fixed infusion rates, are no longer necessary. Therefore, these programmable pumps can also be used for infusion of drug concentrates. At present, however, high costs and the battery-dependent limited duration of functioning of these devices are disadvantageous. As with cardiac pacemakers, battery exchange is necessary. Using implantable drug pumps, relevant changes of body temperature and atmospheric pressure lead to more or less considerable deviations of the infusion rates. These deviations differ from product to product and can be studied in the informative material published by the manufacturer.
Fifteen years ago, on the 28th of August 2004, one of the British pioneers of anaesthesiology, Sir Robert Reynolds Macintosh, died in Oxford. Since he had a major influence on the development of anaesthesia in Europe and the rest of the world, we felt it would be appropriate to review his life and work. Macintosh was the first Nuffield Professor of Anaesthetics in the University of Oxford, so we provide a brief biography of Lord Nuffield and describe the historical background to the creation of the chair. We then outline Sir Robert's early life and describe pre-war developments at Oxford, including the development of the calibrated Oxford vaporizer for ether and laryngoscope. We discuss the wartime research into survival at high altitudes, the design of life-jackets and the efficiency of methods of artificial ventilation, and then show how Sir Robert pioneered a more open approach to the problem of anaesthetic-related deaths. We list some of the anaesthesiological textbooks which were translated into German, and then describe how his overseas travels influenced the teaching of anaesthesiology all over the world. We record Sir Robert Macintosh's connections with East and West Germany and note how he encouraged the development of academic departments of anaesthesia worldwide.
Total intravenous anaesthesia has recently gained more interest in paediatric anaesthesia. However, the global experience with children is limited, therefore, the knowledge acquired in adult practice is often applied uncritically to the paediatric patient. Induction of anaesthesia by mask is a widely used and generally accepted technique; it has gained even more popularity since the introduction of sevoflurane into clinical practice. This drug has markedly improved the safety because of the reduced cardiovascular side-effects. The availability of venous access is a prerequisite for intravenous induction. Pain on injection, bradycardia, and difficulties in dosing the individual patient are the main drawbacks. Inhaled anaesthetics allow to monitor breath by breath the individual pharmacokinetics. On the other hand, maintenance of anaesthesia by an intravenous infusion of propofol is mainly based on assumptions, even when the drug is administered by computer-controlled pumps. Large aberrations from the predicted values can occur in the individual patient. Intraoperative awareness is possible, however, its incidence is generally underestimated. Paravenous infusion and pump dysfunction are typical complications of an intravenous technique. A reduced incidence of postoperative vomiting and agitation are recognised advantages of an intravenous technique. Propofol-infusion-syndrome results from prolonged administration in children and in adults. It can even occur after the use of the substance for a few hours. The duration of a safe period for administration is completely unknown, especially for neonates and infants. In summary, both techniques can be used in children; both have advantages and drawbacks. Because the experience with small children is very limited, we have to re-evaluate our practice with a critical eye day by day.
Remifentanil is an esterase-metabolized ultra-short acting mu-agonist opioid with a rapid clearance. The aim of this study was to determine the efficacy of remifentanil infusion for the short-lasting, but painful, transvaginal puncture for oocyte retrieval. Eighty consenting adult women (ASA I and II) aged 30.5 +/- 5 years and with a body weight of 69.1 +/- 9.1 kg were enrolled in this prospective study. After an oral premedication with 7.5 mg midazolam, all patients received 3 l/min oxygen. Subsequently, the remifentanil infusion was started with a rate of 0.3 microg/kg/min. Remifenanil doses were adjusted as needed for painless puncture and sufficient oxygen saturation in steps of 0.05 microg/kg/min. Dosage requirements, blood pressure, heart rate, oxygen saturation (pulse oxymetry, SaO2) and the level of analgesia were recorded every 3 minutes. Follicular aspiration lasted 11.8 +/- 4.1 min and the time of remifentanil infusion was 18.7 +/- 4.6 min. Dosage requirements of remifentanil were 0.3 microg/kg/min in 48.7% of all patients, but 27.8% needed only 0.25 microg/kg/min and 16.6% needed only 0.2 microg/kg/min. However, 4.2% of patients needed 0.35 microg/kg/min and 2.7% of all cases needed 0.4 microg/kg/min. Vital parameters remained nearly unchanged. Oxygen saturation decreased significantly from 99.2 +/- 0.7% to 98.2 +/- 2.4% after 3 min and to 94.9 +/- 7.2% after 10 min. Nine women showed motoric reactions to puncture. In many cases, the infusion of remifentanil after premedication with midazolam provided a suitable and satisfying anaesthesia for oocyte retrieval. Some patients, however, showed motoric reactions to vaginal puncture, while in other cases significant and clinical relevant decreases in Hb-oxygen saturation occurred. Therefore, we no longer carry out remifentanil infusion for transvaginal oocyte retrieval. We now prefer a remifentanil infusion of 0.2 microg/kg/min and propofol (1 mg/kg initially with intermittent doses of 0.5 mg/kg) combined with assisted ventilation by mask.